David Slack, co-founder of Kinagen Inc, has been appointed head of corporate and business development at NovImmune SA in Geneva, Switzerland. Mr Slack has extensive experience in deal-making including negotiating partnerships, spin-outs, financings and mergers and acquisitions. Prior to co-founding Kinagen, he served as vice president of business development at Isis Pharmaceuticals Inc.
NovImmume also announced that Michael Steinmetz, managing director of Clarus Ventures, has joined its board of directors. Dr Steinmetz is a venture capitalist and former executive of Hoffmann-La Roche.
NovImmune, which develops antibody-based drugs, announced the appointments on 13 July 2012.
Copyright 2012 Evernow Publishing Ltd